跳至主要内容
临床试验/EUCTR2005-000028-17-ES
EUCTR2005-000028-17-ES招募中不适用

Eficacia virológica, inmunológica y trascendencia clínica del efecto de la lamivudina en pacientes portadores de la mutación M184V/I con fracaso terapéutico.

DAVID DALMA0 个研究点开始时间: 2006年4月4日最近更新:
相关药物

试验速览

阶段
不适用
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Age > or =18 years old.
  • Confirmed diagnosis of HIV-1 infection.
  • Sign informed consent.
  • Previous antiretroviral treatment must not be modified in the previous 3 months.
  • Viral load > 1000 copies/ml at the inclusion time.
  • Analysis of genotypic resistance with presence of M184V/I mutation.
  • Presence in genotypic test of M184V + 2 mutations to the following:
  • Nucleoside analog (M41L, D67N, K64R, K70R, L74V, V75I/T/M/S/A, L210W, T215Y/F, K219Q/E/N, Q151M, T69S, E44D, V118I).
  • Protease inhibitor (D30N, L33I/F/V, M46I/L, G48V, I50V/L, I54V, V82A/F/I/T/S, I84V, L90M).
  • No nucleoside analog (K103N, L100I, V106A, V108I, Y181C/I, Y188L, G190S/A).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Active infection in the previous month.
  • Pregnancy woman or women willing to be pregnant during the study.
  • Selection of lamivudine in the rescue treatment of the patient.
  • Inclusion of emtricitabine in the rescue treatment of the patient.

研究者

发起方
DAVID DALMA

相似试验